Journal Article

Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment

Fujiyama, Shigetoshi, Kamo, Yasuhiro, Ueki, Yukitaka, Arima, Nobuyuki, Ito, Masahiro, Mori, Shunsuke

2018

Overview

The mechanism of liver injury with low-dose methotrexate (MTX) is incompletely understood. This study was designed to evaluate the association between non-alcoholic fatty liver disease (NAFLD) and liver injury during MTX treatment for rheumatoid arthritis (RA). Between October 2014 and May 2015, we enrolled all MTX users for RA and monitored participant serum hepatic transaminase levels for 1 year. All patients had normal transaminase levels before the first MTX prescription. Using diagnostic criteria for non-alcoholic steatohepatitis (NASH), we performed histological analyses for patients presenting persistent transaminitis, defined as elevations of hepatic transaminases in four of six determinations during the follow-up period. Possible risk factors for persistent transaminitis were also examined. We followed 846 RA patients with a mean cumulative MTX dose of 2.48 g and identified 51 patients presenting persistent transaminitis. According to multivariate logistic regression analysis, obesity (odds ratio [OR] 3.23, p < 0.001), type 2 diabetes (OR 3.52, p = 0.001), hypercholesterolemia (OR 2.56, p = 0.004), and hyperuricemia (OR 3.52, p = 0.019), which are recognized as risk factors for NAFLD, were independently associated with a risk of persistent transaminitis. Among patients with persistent transaminitis, 42 showed fatty liver at ultrasonography. These patients had no evidence of alcoholic fatty liver, chronic viral hepatitis, autoimmune liver diseases, or hereditary liver diseases. Biopsy specimens were obtained from 32 patients, and we found that a NASH-like pattern was the most prevalent histological abnormality. There was no significant impact of MTX dose and duration on the histological severity. Risk factors and histological findings are similar between NAFLD/NASH and liver injury during low-dose MTX treatment for RA, which suggests a strong association between both entities. NAFLD/NASH may be an underlying condition causing persistent transaminitis in MTX-treated RA patients. The results of this study illustrate the need for monitoring liver injury in RA patients with NAFLD risk factors during MTX treatment.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Aged / Analysis / Antirheumatic Agents - adverse effects / Antirheumatic Agents - therapeutic use / Arthritis / Arthritis, Rheumatoid - diagnostic imaging / Arthritis, Rheumatoid - drug therapy / Arthritis, Rheumatoid - metabolism / Arthritis, Rheumatoid - pathology / Autoimmune diseases / Biology and Life Sciences / Biopsy / Care and treatment / Chemical and Drug Induced Liver Injury - diagnostic imaging / Chemical and Drug Induced Liver Injury - metabolism / Chemical and Drug Induced Liver Injury - pathology / Diabetes / Diabetes mellitus / Diabetes mellitus (non-insulin dependent) / Diagnosis / Diagnostic systems / Dosage and administration / Drug dosages / Drug therapy / Fatty liver / Female / Gastroenterology / Hepatitis / Hepatology / Hospitals / Humans / Hypercholesterolemia / Hypertension / Hyperuricemia / Immunomodulators / Injuries / Liver / Liver - diagnostic imaging / Liver - drug effects / Liver - pathology / Liver biopsy / Liver diseases / Male / Medical treatment / Medicine and Health Sciences / Methotrexate / Methotrexate - adverse effects / Methotrexate - therapeutic use / Middle Aged / Non-alcoholic Fatty Liver Disease - chemically induced / Non-alcoholic Fatty Liver Disease - diagnostic imaging / Non-alcoholic Fatty Liver Disease - metabolism / Non-alcoholic Fatty Liver Disease - pathology / Pathology / Patient outcomes / Patients / Psoriasis / Regression analysis / Rheumatic diseases / Rheumatoid arthritis / Rheumatology / Risk analysis / Risk Factors / Shinto / Systematic review / Transaminase / Transaminases / Transaminases - metabolism / Treatment outcome / Ultrasound